Major adverse cardiovascular events and hyperuricemia as an effect-modifying factor in kidney transplant recipients

Table 1 Sociodemographic and disease-related characteristics of study participants, n (%)

Variable
Sociodemographic data
Male gender	283 (51.9)
Age, median (25%-75%), min-max (years)	55.0 (41.0–64.0), 15.0–89.0
body mass index, median (25%-75%), min-max (kg/m2)	24.5 (22.8–28.4), 15.4–42.6
Current smokers	165 (30.3)
Problems and treatments related to cardiovascular function
Having major adverse cardiovascular events (cardiovascular of cerebrovascular events)	145 (26.6)
Having hypertension	474 (87.0)
Having left ventricular hypertrophy	431 (79.1)
Having dyslipidemia	426 (78.2)
Having previous cardiovascular events	79 (14.5)
Problems and treatments related to the urine system
UA, median (25%-75%), min-max (μmol/L)	436.0 (357.0–514.5), 201.0–761.0
Having elevated UA	116 (21.3)
Having a very high level of UA	194 (35.6)
Having hyperuricemia	347 (63.7)
Glomerular filtration rate, median (25%-75%), min-max (mL/minute)	45.0 (24.0–64.0), 6.0–116.0
Having proteinuria	172 (31.6)
Using steroids for more than one year	411 (75.4)
Acute transplant rejection	182 (33.4)
Receiving hyperuricemia treatment	191 (35.0)
Calcineurin therapy-receiving cyclosporine therapy	111 (20.4)
Calcineurin therapy-receiving tacrolimus therapy	404 (74.0)
Other functions and diseases
New onset of diabetes mellitus	82 (15.0)
Length of hemodialysis, median (25%-75%), min-max (months)	12.0 (7.0–23.0), 0.0–131.0
HPT, median (25%-75%), min-max (pg/mL)	120.0 (73.0–180.0), 23.0-1023.0
Having secondary HPT (> 90 pg/mL)	375 (68.8)
Inflammation, median (25%-75%), min-max (mg/L)	3.6 (1.3–5.5), 0.0-130.0
Having inflammation (> 5 mg/L)	145 (26.6)
Having anemia (hemoglobin level < 13 g/dL in male and < 12 g/dL in female)	180 (33.0)

HPT: Hyperparathyroidism; Min: Minimum; Max: Maximum; UA: Uric acid.